Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial

Research output: Contribution to journalJournal articleResearchpeer-review

To evaluate the efficacy of combining the dual endothelin receptor antagonist, bosentan, and the phosfodiesterase-5-inhibitor, sildenafil, in patients with Eisenmenger syndrome.
Original languageEnglish
JournalEuropean Heart Journal
Volume31
Issue number9
Pages (from-to)1124-31
Number of pages8
ISSN0195-668X
DOIs
Publication statusPublished - 1 May 2010

ID: 34080333